Matthew Stanton, CFA
Stock Analyst at Jefferies
(1.28)
# 3,703
Out of 4,993 analysts
23
Total ratings
57.1%
Success rate
-3.3%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton, CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TKNO Alpha Teknova | Initiated Coverage: Buy | $9 | $8.34 | +7.91% | 1 | Sep 17, 2026 | |
| BLFS BioLife Solutions | Downgraded: Hold | $22 → $31 | $37.18 | -16.62% | 2 | Jul 23, 2026 | |
| CYRX Cryoport | Reiterated: Hold | $9.5 → $13 | $17.62 | -26.22% | 6 | Jun 8, 2026 | |
| RGEN Repligen | Reiterated: Hold | $135 → $142 | $180.71 | -21.42% | 7 | May 5, 2026 | |
| AZTA Azenta | Reiterated: Buy | $42 → $35 | $33.75 | +3.70% | 5 | Apr 1, 2026 | |
| MRVI Maravai LifeSciences Holdings | Reiterated: Buy | $10 | $7.17 | n/a | 1 | Mar 18, 2025 | |
| LAB Standard BioTools | Initiated Coverage: Buy | $3.25 | $0.7419 | n/a | 1 | Apr 4, 2024 |
Alpha Teknova
Sep 17, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $8.34
Upside: +7.91%
BioLife Solutions
Jul 23, 2026
Downgraded: Hold
Price Target: $22 → $31
Current: $37.18
Upside: -16.62%
Cryoport
Jun 8, 2026
Reiterated: Hold
Price Target: $9.5 → $13
Current: $17.62
Upside: -26.22%
Repligen
May 5, 2026
Reiterated: Hold
Price Target: $135 → $142
Current: $180.71
Upside: -21.42%
Azenta
Apr 1, 2026
Reiterated: Buy
Price Target: $42 → $35
Current: $33.75
Upside: +3.70%
Maravai LifeSciences Holdings
Mar 18, 2025
Reiterated: Buy
Price Target: $10
Current: $7.17
Upside: n/a
Standard BioTools
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $3.25
Current: $0.7419
Upside: n/a